Transaction Search Form: please type in any of the fields below.
Date: April 29, 2024 Mon
Time: 11:55 pm
Time: 11:55 pm
Results for psychoactive substances
3 results foundAuthor: DrugScope Title: Business as usual? A status report on new psychoactive substances (NPS) and 'club drugs' in the UK Summary: Since 2008-2009, there has been a significant increase in interest in, and probable use of, a new breed of synthetic drugs, which can be grouped together under the term New Psychoactive Substances (NPS). The Advisory Council on the Misuse of Drugs (A) defines NPS as "psychoactive drugs which are not prohibited by the United Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs Act 1971 and which people in the UK are seeking for intoxicant use". Some definitions, particularly from outside the UK, also include so-called 'club drugs' such as ketamine and GHB/GBL that are not included in the UN Convention on Psychotropic Substances. This brief, status report, encompasses both NPS and 'club drugs' and gives an overview of current sector knowledge and experience on these substances, with consideration given to: - how and why NPS developed; - what we know (and don't know) about prevalence and patterns of use; - early warning systems in place for information sharing; - enforcement and legislative responses; - health impacts and drug-related deaths; - public health information and harm reduction interventions; - case studies of existing treatment and service-level responses. The report is intended to be of use to frontline drug and alcohol workers, managers and commissioners, as well as policy makers. Details: London: DrugScope, 2014. 25p. Source: Internet Resource: Accessed September 10, 2014 at: http://www.drugscope.org.uk/Resources/Drugscope/Documents/PDF/Policy/BusinessAsUsual.pdf Year: 2014 Country: United Kingdom URL: http://www.drugscope.org.uk/Resources/Drugscope/Documents/PDF/Policy/BusinessAsUsual.pdf Shelf Number: 133268 Keywords: Club DrugsDrug Abuse and Addiction (U.K.)Drug Abuse TreatmentDrug EnforcementPsychoactive DrugsPsychoactive Substances |
Author: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Title: New psychoactive substances in Europe. An update from the EU Early Warning System Summary: This short report provides an update on new psychoactive substances (NPS) in Europe for 2014. It highlights recent developments, including the growth of the market over the past few years, as illustrated by seizures by law enforcement and other indicators, as well as the growing number of serious harms that are being reported as a result. Details: Lisbon: EMCDDA, 2015. 12p. Source: Internet Resource: Accessed April 15, 2015 at: http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf Year: 2015 Country: Europe URL: http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf Shelf Number: 135226 Keywords: Drug Enforcement Drug Markets Illegal Drugs (Europe) Psychoactive Substances |
Author: Ali, Farihah Title: Synthetic Cannabinoid Use in Correctional Populations - An Emerging Challenge for Offender Health and Safety? A Brief Review Summary: Synthetic cannabinoids (SCs) have become increasingly popular among various user populations, and have arisen as common alternatives to organic cannabis products. SCs are an emerging category of drugs under the umbrella of New Psychoactive Substances (NPS). They belong to a continually evolving series of synthetic psychoactive product groups, based on successive structural modifications, commonly marketed as herbal mixtures which mimic cannabis' psychoactive effects, and are classified as 'legal highs'. SCs, however, have been associated with a variety of distinct adverse health outcomes (especially acute), some of which are considered more severe than those which result from the use of natural cannabis products. Compared to natural cannabis products, SCs pose threats to users' health, including: elevated levels of cardio-vascular problems, kidney problems, seizures, acute hallucinations, psychosis and anxiety, among others. Various jurisdictions have reported high numbers of presentations to emergency departments, as well as cases of mortality, directly related to the use of SCs. While all forms of SCs are banned in correctional institutions, existing evidence suggests that they have become increasingly popular among offenders, and as such, pose distinct novel challenges for correctional administrations charged with the responsibility for offender health and safety. SC use results in potentially powerful stimulant effects which may make them attractive for use by offenders, but may also result in adverse outcomes which come with potentially undesirable or hazardous consequences for offender behaviour and safety. Moreover, SCs evade major routine drug interdiction and drug testing systems in operation in correctional systems, and hence are attractive for illicit use, trade, and import in correctional settings. To better understand SC use, and the possible health and safety consequences for offenders, this report reviewed pertinent national and international literature on SC use, availability, and related health outcomes among general and correctional populations. Research data on SCs in the context of Canadian correctional systems are currently limited, and are thus urgently required. Educating offenders and correctional staff on the risks of SC use is imperative, and correctional systems should prepare for the potential health and safety consequences of increased SC use while awaiting the results and guidance offered by future research. Details: Ottawa: Correctional Service of Canada, 2017. 24p. Source: Internet Resource: 2017 No.R-397: Accessed March 13, 2018 at: http://publications.gc.ca/collections/collection_2017/scc-csc/PS83-3-397-eng.pdf Year: 2017 Country: Canada URL: http://publications.gc.ca/collections/collection_2017/scc-csc/PS83-3-397-eng.pdf Shelf Number: 149456 Keywords: Correctional InstitutionsDrug Abuse and AddictionDrug OffendersHealth CarePrisonersPsychoactive Substances |